Alembic Pharmaceuticals Limited today announced a significant milestone with the US Food and Drug Administration’s (USFDA) final approval of its Abbreviated New Drug Application (ANDA) for Nelarabine Injection, 250 mg/50 mL (5 mg/mL). This single-dose vial formulation is therapeutically equivalent to Sandoz Inc.’s Arranon Injection. Nelarabine, a nucleoside metabolic inhibitor, is a critical treatment for …